
Release date: 2026-01-26 17:46:01 Article From: Lucius Laos Recommended: 18
Concurrent use of this medicine with any of the following medications is generally not recommended, but may be necessary in certain circumstances. If both medications are prescribed together, your doctor may adjust the dosage or frequency of administration of one or both drugs.
Relevant drugs include abametapir, acalabrutinib, live adenovirus type 4 vaccine, live adenovirus type 7 vaccine, alfentanil, amiodarone, amlodipine, aprepitant, atogepant, atrasentan, avacopan, avanafil, avapritinib, bedaquiline, benzhydrocodone, betrixaban, boceprevir, bosentan, bosutinib, brigatinib, budesonide, buprenorphine, bupropion, buspirone, cabozantinib, capmatinib, cariprazine, cenobamate, cholera vaccine, clarithromycin, cobicistat, cobimetinib, codeine, conivaptan, crizanlizumab, cyclosporine, dabigatran etexilate, dalidazole, darifenacin, etc. In addition, there are many other drugs for which attention should be paid to concurrent use; specific management and adjustments should be carried out in accordance with the doctor's advice.
Certain medications should not be used during meals or before/after consuming specific types of food, as interactions may occur. Concurrent use of alcohol or tobacco with certain medications may also lead to interactions. Please discuss with your healthcare professional the use of this medicine together with food, alcohol, or tobacco.
The presence of other medical conditions may affect the use of this medicine. Be sure to inform your doctor if you have any other health problems, especially the following:
1. A history of depression.
2. Diabetes mellitus.
3. Cardiac rhythm disorders.
4. Hyperglycemia (high blood sugar levels).
5. Hyperlipidemia (high fat levels in the blood).
6. Hypertension (high blood pressure).
7. Pulmonary or respiratory disorders.
8. A history of seizures — use with caution. This may exacerbate these conditions.
9. Severe renal impairment.
10. Moderate or severe hepatic impairment — use with caution. The effects of the drug may be enhanced due to reduced elimination from the body.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:732025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3692024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:652025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:822025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:822025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:982025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:942025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:952025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: